IQVIA Holdings Inc. (NYSE:IQV) is among the 10 Best Consensus Buy-Rated Stocks to Invest in. On February 11, 2026, Morgan Stanley lowered its price target on IQVIA Holdings Inc. (NYSE:IQV) to $240 ...
Barchart on MSN
Is Wall Street bullish or bearish on IQVIA Holdings stock?
Durham, North Carolina-based IQVIA Holdings Inc. (IQV) provides healthcare research services. Valued at $28 billion by market ...
IQVIA Holdings (NYSE:IQV) is expanding its AI driven clinical research solutions and signing new commercial collaborations tied to advanced data services. The company has entered a long term ...
Zacks Investment Research on MSN
Unlocking IQVIA (IQV) international revenues: Trends, surprises, and prospects
Have you evaluated the performance of IQVIA Holdings' (IQV) international operations for the quarter ending December 2025? Given the extensive global presence of this clinical testing company, ...
IQVIA reported strong Q4 2023 earnings, exceeding market expectations, and issued bullish guidance for 2024. The company's R&DS segment saw record net new bookings, indicating high demand for their ...
Feb 5 (Reuters) - Healthcare data and clinical research provider IQVIA Holdings on Thursday forecast annual profit below Wall ...
IQVIA Exceeds Expectations With Robust Q3 Results; Raising FVE to $276 on Improved Near-Term Outlook
Financial Strength IQVIA is in decent financial health, with strong cash flow generation from both its clinical research and technology businesses offset by an above-average debt load. The company ...
A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at A replay of the webcast will be available later that day. IQVIA (NYSE:IQV) is a leading global ...
IQVIA is trading at 18.2x, which is a discount compared to the industry average of 35.2x. IQV has better operating margins, operational efficiency, strong cash flows, and moderate leverage. The life ...
The immediate catalyst for the recent decline was the company's financial outlook for fiscal year 2026. Management projected adjusted earnings per share in a range of $12.55 to $12.85, falling short ...
Financial Strength IQVIA is in decent financial health, with strong cash flow generation from both its clinical research and technology businesses offset by an above-average debt load. The company ...
The clinical trial lab services provider Q2 Solutions has fallen short of its commitment to create nearly 750 jobs and invest $73 million in Research Triangle Park. A subsidiary of IQVIA, Q2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results